Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

QDMRK was a phase III clinical trial of raltegravir given once daily (QD) (800-mg dose) versus twice daily (BID) (400 mg per dose), each in combination with once-daily coformulated tenofovir-emtricitabine, in treatment-naive HIV-infected patients. Pharmacokinetic (PK) and pharmacokinetic/pharmacodyn...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rizk, Matthew L., Hang, Yaming, Luo, Wen-Lin, Su, Jing, Zhao, Jing, Campbell, Havilland, Nguyen, Bach-Yen T., Sklar, Peter, Eron, Joseph J., Wenning, Larissa
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2012
Konular:
Antiviral Agents
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3370742/
https://ncbi.nlm.nih.gov/pubmed/22430964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.06417-11
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller